New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Multiple Sclerosis
FDA Approves Shorter Infusion Time for MS Drug Ocrevus
The approval was based on data from the phase 3b ENSEMBLE PLUS study that compared the frequency and severity of infusion-related reactions for a 2-hour Ocrevus infusion time to the previously approved 3.5-hour infusion time in patients with relapsing-remitting MS.
New Drug Product: Bafiertam
This slideshow shows drug information for Bafiertam. Click here for the complmultiete Bafiertam monograph.
New Drug Product: Kesimpta
This slideshow shows drug information for Kesimpta. Click here for the complete Kesimpta monograph.
Bafiertam Now Available for Relapsing Forms of Multiple Sclerosis
Bafiertam is a novel fumarate bioequivalent alternative to its prodrug dimethyl fumarate.
Kesimpta Approved for Relapsing Forms of Multiple Sclerosis
Kesimpta, a CD20-directed cytolytic monoclonal antibody, is the first B-cell therapy intended for patient self-administration.
Mylan Launches Generic Version of Tecfidera for MS
This is the first FDA-approved therapeutically equivalent, substitutable generic of Tecfidera.
Complementary, Alternative Medicine Use Increasing for MS
Ninefold increase observed in likelihood of patients speaking to their neurologist about CAM use.
Therapeutic Hookworm Explored for Relapsing Multiple Sclerosis
No effect seen for hookworm vs placebo on number of new/enlarging/enhancing lesions.
New Oral Treatment for Relapsing Forms of MS Now Available
Zeposia® (ozanimod; Bristol Myers Squibb) is now available for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
